Company Profile

Anchored in the long term vision of the Founders to tackle address cures for cancer by early stage screening Lariat founder and personnel are employing biochemical methods to identify rare cancer-causing genetic variants to the firm's microfluidic chip technologies. Management anchor the firm's effort in the primary technological goal of developing a system of droplet-based microfluidics with electronic detection and robust operation, as well as proprietary biochemical methods for allele-specific enrichment of mutant DNA related to cancer within hydrogel microparticles.